Featured News

A year has passed since Celiac Disease Foundation launched its patient registry, iCureCeliac®. Since our launch, 2,300 participants have contributed their medical information and experiences living with celiac disease and…

ImmusanT, a Cambridge, MA-based biotechnology company, has announced that Nexvax2®, an immunotherapy drug designed to protect celiac disease patients from gluten exposure, has successfully completed a Phase 1b clinical trial…

The March 19, 2017 Summit brought patients and consumer advocates together with guideline developers, methodologists, and other stakeholders in the clinical guideline enterprise for the purpose of constructive dialogue and initiation of durable relationships between them.

At the March 9 and 10, 2017 Genetic Alliance Conference, Celiac Disease Foundation worked to determine best strategies to help grow our iCureCeliac® patient registry, and to encourage patients and their family members to engage in the research process to influence the future of celiac disease research toward treatments and a cure.

At the March 5 and 6, 2017 Digestive Disease National Coalition Public Policy Forum, Celiac Disease Foundation, together with representatives from digestive disease organizations across the United States, developed common agendas to influence healthcare policy.

Celiac Disease Foundation, in partnership with the University of Southern California (USC) Keck School of Medicine, and CDF Board member Dr. Michael S. Karp, Chief of the Division of Geriatric,…

ImmusanT, a Cambridge, MA-based biotechnology company, has announced that Nexvax2®, an immunotherapy drug designed to protect celiac disease patients from gluten exposure, has successfully completed a Phase 1b clinical trial…

In 1992, M.N. Marsh published a study aimed at measuring degrees of change seen in the structure of intestinal villi under microscopic scrutiny. Villi are finger-like projections which line the…

In addition to improving treatments and finding a cure for celiac disease, iCureCeliac® is helping researchers appreciate the realities of living with celiac disease, helping to influencing what they choose to research and why.

Patients with chronic diseases and their caregivers are demanding that any new health plan that emerges from Congress retains specific patient protections, including prohibiting pre-existing condition discrimination.